Autoimmune Encephalitis and Its Relation to Infection

Current Neurology and Neuroscience Reports

Volumn 15, Issue 3, 2015, Pages

  Venkatesan, Arun ^a   Benavides, David R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti NMDA receptor antibodies; Autoimmune encephalopathy; CNS autoimmunity; FIRES; Molecular mimicry; Rasmussen s syndrome

Indexed keywords

ACICLOVIR; AMPA RECEPTOR; AUTOIMMUNE REGULATOR PROTEIN; BUNGAROTOXIN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANZYME B; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MUNC18 PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; POSTSYNAPTIC PROTEIN 95; PROTEIN ANTIBODY; STEROID; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER;

AIRE GENE; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; AUTOIMMUNE DISEASES; AUTOIMMUNE ENCEPHALITIS; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CEREBROSPINAL FLUID; COMPLICATION; CTL4A GENE; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; ENCEPHALITIS; EPSTEIN BARR VIRUS; ETIOLOGY; FEBRILE INFECTION RELATED EPILEPSY SYNDROME; FOXP3 GENE; GENETIC ASSOCIATION; GLIA CELL; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOPATHOGENESIS; INFECTION; LYMPHOCYTE SUBPOPULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PLEOCYTOSIS; POLYMERASE CHAIN REACTION; PROTEIN FOLDING; PROTEIN PROCESSING; PTPN22 GENE; RASMUSSEN SYNDROME; REVIEW; SEIZURES, FEBRILE; SYMPTOMATOLOGY; TNFA GENE;

ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; AUTOIMMUNE DISEASES; COMPLICATIONS; ENCEPHALITIS; ENCEPHALITIS, HERPES SIMPLEX; ETIOLOGY; HUMANS; IMMUNOLOGY; SEIZURES, FEBRILE;

EID: 84963985369     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-015-0529-1     Document Type: Review

References (74)

1. Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008;47:303–27.
2. Venkatesan A, Tunkel AR, Bloch KC, Lauring AS, Sejvar J, Bitnun A, et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis. 2013;57:1114–28.
3. Sejvar JJ, Kohl KS, Bilynsky R, Blumberg D, Cvetkovich T, Galama J, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25:5771–92.
4. Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10:835–44.
5. Kolski H, Ford-Jones EL, Richardson S, Petric M, Nelson S, Jamieson F, et al. Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995. Clin Infect Dis. 1998;26:398–409.
6. Ball R, Halsey N, Braun MM, Moulton LH, Gale AD, Rammohan K, et al. Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the vaccine: Adverse Event Reporting System. J Clin Epidemiol. 2002;55:819–24.
7. Mailles A, Stahl JP. Infectious encephalitis in France in 2007: a national prospective study. Clin Infect Dis. 2009;49:1838–47.
8. Granerod J, Cousens S, Davies NW, Crowcroft NS, Thomas SL. New estimates of incidence of encephalitis in England. In: Emerg Infect Dis [Internet]. Edited by; 2013;19(9). http://dx.doi.org/10.3201/eid1909.130064.
9. George BP, Schneider EB, Venkatesan A. Encephalitis hospitalization rates and inpatient mortality in the United States, 2000-2010. PLoS One. 2014;9:e104169.
10. Glaser CA, Honarmand S, Anderson LJ, Schnurr DP, Forghani B, Cossen CK, et al. Beyond viruses: clinical profiles and etiologies associated with encephalitis. Clin Infect Dis. 2006;43:1565–77.
11. Mailles A, Stahl JP. Infectious encephalitis in France in 2007: a national prospective study. Clin Infect Dis. 2009;49:1838–47.
12. Graus F, Dalmau J. Paraneoplastic neurological syndromes. Curr Opin Neurol. 2012;25:795–801.
13. Irani SR, Gelfand JM, Al-Diwani A, Vincent A. Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol. 2014;76:168–84.
14. Thakur KT, Motta M, Asemota AO, Kirsch HL, Benavides DR, Schneider EB, et al. Predictors of outcome in acute encephalitis. Neurology. 2013;81:793–800.
15. Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65. A large observational study of 577 patients, including 211 pediatric patients, with anti-NMDAR antibodies provides data on response to therapy, longitudinal outcomes, and prognostic factors.
16. Venkatesan A, Geocadin RG. Diagnosis and management of acute encephalitis: a practical approach. Neurol Clin Pract. 2014;4:206–15.
17. Miller FW, Pollard KM, Parks CG, Germolec DR, Leung PS, Selmi C, et al. Criteria for environmentally associated autoimmune diseases. J Autoimmun. 2012;39:253–8.
18. Atassi MZ, Casali P. Molecular mechanisms of autoimmunity. Autoimmunity. 2008;41:123–32.
19. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12:623–35.
20. Kapadia M, Sakic B. Autoimmune and inflammatory mechanisms of CNS damage. Prog Neurobiol. 2011;95:301–33.
21. Venkatesan A, Johnson RT. Infections and multiple sclerosis. Handb Clin Neurol. 2014;122:151–71.
22. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 2006;19:80–94.
23. Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol. 1995;7:812–8.
24. Alves-Leon SV, Veluttini-Pimentel ML, Gouveia ME, Malfetano FR, Gaspareto EL, Alvarenga MP, et al. Acute disseminated encephalomyelitis: clinical features, HLA DRB1*1501, HLA DRB1*1503, HLA DQA1*0102, HLA DQB1*0602, and HLA DPA1*0301 allelic association study. Arq Neuropsiquiatr. 2009;67:643–51.
25. Shwetank, Date OS, Kim KS, Manjunath R. Infection of human endothelial cells by Japanese encephalitis virus: increased expression and release of soluble HLA-E. PLoS One. 2013;8(11):e79197.
26. Clarke P, Leser JS, Bowen RA, Tyler KL. Virus-induced transcriptional changes in the brain include the differential expression of genes associated with interferon, apoptosis, interleukin 17 receptor A, and glutamate signaling as well as flavivirus-specific upregulation of tRNA synthetases. MBio. 2014;5:e00902–14.
27. Gregersen PK, Behrens TW. Genetics of autoimmune diseases—disorders of immune homeostasis. Nat Rev Genet. 2006;7:917–28.
28. de Aquino MT, Kapil P, Hinton DR, Phares TW, Puntambekar SS, Savarin C, et al. IL-27 limits central nervous system viral clearance by promoting IL-10 and enhances demyelination. J Immunol. 2014;193:285–94.
29. Cervantes-Barragán L, Firner S, Bechmann I, Waisman A, Lahl K, Sparwasser T, et al. Regulatory T cells selectively preserve immune privilege of self-antigens during viral central nervous system infection. J Immunol. 2012;188:3678–85.
30. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63–74.
31. Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, et al. Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66:11–8.
32. Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, Iigaya M, et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology. 2008;70:504–11.
33. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133:1655–67.
34. Gable MS, Gavali S, Radner A, Tilley DH, Lee B, Dyner L, et al. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis. 2009;28:1421–9.
35. Prüss H, Finke C, Höltje M, Hofmann J, Klingbeil C, Probst C, et al. N-methyl-d-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol. 2012;72:902–11. This is the first report of anti-NMDAR antibodies in patients with herpes simplex encephalitis with retrospective analysis of 44 patients with proven HSE, 13 of which were found to have anti-NMDAR in the course of HSE.
36. Leypoldt F, Titulaer MJ, Aguilar E, Walther J, Bönstrup M, Havemeister S, et al. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. Neurology. 2013;81:1637–9.
37. Desena A, Graves D, Warnack W, Greenberg BM. Herpes simplex encephalitis as a potential cause of anti-N-methyl-d-aspartate receptor antibody encephalitis: report of 2 cases. JAMA Neurol. 2014;71:344–6.
38. Wickström R, Fowler A, Cooray G, Karlsson-Parra A, Grillner P. Viral triggering of anti-NMDA receptor encephalitis in a child—an important cause for disease relapse. Eur J Paediatr Neurol. 2014;18:543–6.
39. Mohammad SS, Sinclair K, Pillai S, Merheb V, Aumann TD, Gill D, et al. Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-methyl-d-aspartate receptor or dopamine-2 receptor. Mov Disord. 2014;29:117–22.
40. Bektaş O, Tanyel T, Kocabaş BA, Fitöz S, Ince E, Deda G. Anti-N-methyl-d-aspartate receptor encephalitis that developed after herpes encephalitis: a case report and literature review. Neuropediatrics. 2014;45(6):396–401.
41. Hacohen Y, Deiva K, Pettingill P, Waters P, Siddiqui A, Chretien P, et al. N-methyl-d-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord. 2014;29:90–6.
42. Armangue T, Titulaer MJ, Málaga I, Bataller L, Gabilondo I, Graus F, Dalmau J, Group SA-N-m-D-ARNEW: pediatric anti-N-methyl-d-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr. 2013;162:850–856:e852.
43. Armangue T, Leypoldt F, Málaga I, Raspall-Chaure M, Marti I, Nichter C, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol. 2014;75:317–23. This series of patients with “relapsing post-HSE” and well-characterized serum and CSF contributes to our understanding of the timing and nature of the interaction between HSE, NMDAR antibodies, and a post-HSE immune syndrome.
44. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–8.
45. Gleichman AJ, Spruce LA, Dalmau J, Seeholzer SH, Lynch DR. Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J Neurosci. 2012;32:11082–94. The N368/G369 region of GluN1 is identified as crucial for anti-NMDAR antibody immunoreactivity, and it is shown that antibody binding alters receptor function by increasing open channel time.
46. Planagumà J, Leypoldt F, Mannara F, Gutiérrez-Cuesta J, Martín-García E, Aguilar E, Titulaer MJ, Petit-Pedrol M, Jain A, Balice-Gordon R,Lakadamyali M, Graus F, Maldonado R, Dalmau J. Human N-methyl-d-aspartate receptor antibodies alter memory and behaviour in mice. Brain. 2015;138(Pt 1):94–109.
47. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30:5866–75.
48. Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ. Acute mechanisms underlying antibody effects in anti-N-methyl-d-aspartate receptor encephalitis. Ann Neurol. 2014;76:108–19. Using dissociated neuronal culture, the authors provide biochemical and electrophysiological evidence of antibody-mediated downregulation of surface NMDARs independent of NMDAR activity, and show evidence of homeostatic synaptic plasticity mechanisms with a decrease in inhibitory synapse density onto excitatory hippocampal neurons.
49. Mikasova L, De Rossi P, Bouchet D, Georges F, Rogemond V, Didelot A, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 2012;135:1606–21. High-resolution nanoparticle imaging and live imaging is used to shed light on cellular and molecular mechanisms of anti-NMDAR autoantibody pathogenic mechanisms, implicating dysfunction of NMDAR-EphB2R interactions in the trafficking abnormalities of synaptic and extrasynaptic NMDAR.
50. Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci. 2014;1–21.
51. Armangue T, Titulaer MJ, Sabater L, Pardo-Moreno J, Gresa-Arribas N, Barbero-Bordallo N, et al. A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. Ann Neurol. 2014;75:435–41.
52. Panzer JA, Gleichman AJ, Lynch DR. Glutamatergic autoencephalitides: an emerging field. J Neural Transm. 2014;121:957–68.
53. Bien CG, Granata T, Antozzi C, Cross JH, Dulac O, Kurthen M, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain. 2005;128:454–71.
54. Varadkar S, Bien CG, Kruse CA, Jensen FE, Bauer J, Pardo CA, et al. Rasmussen’s encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol. 2014;13:195–205.
55. RASMUSSEN T, OLSZEWSKI J, LLOYDSMITH D. Focal seizures due to chronic localized encephalitis. Neurology. 1958;8:435–45.
56. Rogers SW, Andrews PI, Gahring LC, Whisenand T, Cauley K, Crain B, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen’s encephalitis. Science. 1994;265:648–51.
57. Wiendl H, Bien CG, Bernasconi P, Fleckenstein B, Elger CE, Dichgans J, et al. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen’s encephalitis. Neurology. 2001;57:1511–4.
58. Mantegazza R, Bernasconi P, Baggi F, Spreafico R, Ragona F, Antozzi C, et al. Antibodies against GluR3 peptides are not specific for Rasmussen’s encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol. 2002;131:179–85.
59. Watson R, Jiang Y, Bermudez I, Houlihan L, Clover L, McKnight K, et al. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology. 2004;63:43–50.
60. Watson R, Jepson JE, Bermudez I, Alexander S, Hart Y, McKnight K, et al. Alpha7-acetylcholine receptor antibodies in two patients with Rasmussen encephalitis. Neurology. 2005;65:1802–4.
61. Yang R, Puranam RS, Butler LS, Qian WH, He XP, Moyer MB, et al. Autoimmunity to munc-18 in Rasmussen’s encephalitis. Neuron. 2000;28:375–83.
62. Bien CG, Bauer J, Deckwerth TL, Wiendl H, Deckert M, Wiestler OD, et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen’s encephalitis. Ann Neurol. 2002;51:311–8.
63. Schwab N, Bien CG, Waschbisch A, Becker A, Vince GH, Dornmair K, et al. CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain. 2009;132:1236–46.
64. Owens GC, Huynh MN, Chang JW, McArthur DL, Hickey MJ, Vinters HV, et al. Differential expression of interferon-γ and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response. J Neuroinflammation. 2013;10:56. Brain tissue from patients with RE subjected to quantitative PCR was found to express high levels of Th1-associated genes in the early symptomatic phase of disease, suggesting a role for the Th1 immune response in the pathogenesis of RE.
65. Friedman H, Ch'ien L, Parham D. Virus in brain of child with hemiplegia, hemiconvulsions, and epilepsy. Lancet. 1977;2:666.
66. Jay V, Becker LE, Otsubo H, Cortez M, Hwang P, Hoffman HJ, et al. Chronic encephalitis and epilepsy (Rasmussen’s encephalitis): detection of cytomegalovirus and herpes simplex virus 1 by the polymerase chain reaction and in situ hybridization. Neurology. 1995;45:108–17.
67. Power C, Poland SD, Blume WT, Girvin JP, Rice GP. Cytomegalovirus and Rasmussen’s encephalitis. Lancet. 1990;336:1282–4.
68. Walter GF, Renella RR. Epstein-Barr virus in brain and Rasmussen’s encephalitis. Lancet. 1989;1:279–80.
69. Vinters HV, Wang R, Wiley CA. Herpesviruses in chronic encephalitis associated with intractable childhood epilepsy. Hum Pathol. 1993;24:871–9.
70. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51(4):676–85.
71. van Baalen A, Häusler M, Boor R, Rohr A, Sperner J, Kurlemann G, et al. Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood. Epilepsia. 2010;51:1323–8.
72. Kramer U, Chi CS, Lin KL, Specchio N, Sahin M, Olson H, et al. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia. 2011;52:1956–65. This retrospective multicenter study identified the largest group of children to date who fit criteria for FIRES. The clinical presentations, results of serologic and CSF testing, and neuroimaging results are comprehensively presented.
73. Illingworth MA, Hanrahan D, Anderson CE, O'Kane K, Anderson J, Casey M, et al. Elevated VGKC-complex antibodies in a boy with fever-induced refractory epileptic encephalopathy in school-age children (FIRES). Dev Med Child Neurol. 2011;53:1053–7.
74. van Baalen A, Häusler M, Plecko-Startinig B, Strautmanis J, Vlaho S, Gebhardt B, et al. Febrile infection-related epilepsy syndrome without detectable autoantibodies and response to immunotherapy: a case series and discussion of epileptogenesis in FIRES. Neuropediatrics. 2012;43:209–16.